Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

CHRS EBITDA Margin

EBITDA as a percentage of revenue.

Coherus Oncology, Inc.NASDAQ: CHRS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -275.1%

EBITDA Margin was -275.1% in Q1 FY2026, up 306.6 pp from a year earlier. On a trailing-twelve-month basis it was -341.0%, down 291.0 pp year over year. Over 3 fiscal years it narrowed by 282.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -127.0% for the fiscal year ending Dec 2026, up from -403.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-275.1%+63.8 pp QoQ
Last fiscal yearDec 2025
-403.6%-426.4 pp YoY
LTMMar 2026
-341.0%-291.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+306.6 pp+158.6 pp-148.0 pp
1 year-426.4 pp+276.5 pp+703.0 pp
3 years-282.5 pp+382.5 pp+665.0 pp
5 years+420.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-403.6%
Year-over-year change
-426.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CHRS compares with its peers on the latest reported figures

  • CHRS's LTM Mar 2026 EBITDA Margin of -341.0% is the 7th highest of the 9 companies compared; the peer median is -211.7%.
  • Its year-over-year change of -291.0 pp is the 7th highest of 9, against a peer median of -13.7 pp.
  • Over three fiscal years its change of -282.5 pp compares with a peer median of -29.1 pp.
CHRS Competitors Peer median
EBITDA Margin for CHRS and competitors
Company Period LTM level YoY 3-year change
PLXProtalix BioTherapeutics, Inc.LTM Mar 202629.2% +17.2 pp+17.0 pp
CDXSCodexis, Inc.LTM Mar 2026-28.2% +91.2 pp-29.1 pp
OABIOmniAb, Inc.LTM Mar 2026-117.0% +50.4 pp-225.4 pp
IVVDInvivyd, Inc.LTM Mar 2026-135.5% +244.4 pp—
CCCCC4 Therapeutics, Inc.LTM Mar 2026-287.9% -44.6 pp+113.4 pp
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-339.9% -229.0 pp-131.5 pp
CHRSCoherus Oncology, Inc.LTM Mar 2026-341.0% -291.0 pp-282.5 pp
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-2329.5% -862.2 pp+207.6 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-142957.6% -159600.9 pp-131573.1 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding CHRS) -211.7%-13.7 pp-29.1 pp

Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue326.55M211.04M257.24M266.96M42.17M
Cost of Revenue57.59M70.08M158.99M117.55M17.74M
Gross Profit268.96M140.96M98.25M149.41M24.43M
Gross Margin82.4%66.8%38.2%56.0%57.9%
Research & Development363.11M199.36M109.44M93.34M104.96M
Selling, General & Admin169.71M198.48M185.62M150.44M99M
Operating Expenses532.82M397.84M301.45M261.07M203.97M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
EBITDA(260.69M)(255.58M)(193.94M)60.94M(170.2M)
EBITDA Margin-79.8%-121.1%-75.4%22.8%-403.6%
Operating Income(263.86M)(256.88M)(203.2M)(111.67M)(179.53M)
Operating Margin-80.8%-121.7%-79.0%-41.8%-425.7%
Interest Income00000
Interest Expense22.96M32.47M40.54M27.16M9M
Other Income / Expenses(23.24M)(34.87M)(35.07M)140.17M(3.59M)
Income Before Tax(287.1M)(291.75M)(238.27M)28.51M(183.12M)
Pre-Tax Margin-87.9%-138.2%-92.6%10.7%-434.2%
Income Tax Expense00(380K)00
Net Income(287.1M)(291.75M)(237.89M)28.51M(170.29M)
Net Margin-87.9%-138.2%-92.5%10.7%-403.8%
EPS (Basic)(3.81)(3.76)(2.53)0.25(1.45)
EPS (Diluted)(3.81)(3.76)(2.53)0.25(1.45)
Weighted Avg Shares75.45M77.63M94.16M114.55M120.37M
Weighted Avg Shares (Diluted)75.45M77.63M94.16M114.83M120.37M

Coherus Oncology, Inc.

NASDAQ:CHRS

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.